PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Historical Holders from Q1 2014 to Q3 2025

Symbol
PBYI on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
49.6M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
34.4M
Holdings value
$182M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
131
Number of buys
64
Number of sells
-49
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 8% +18.6% $11.9M $1.99M 3.94M +20.1% Anders Hove 31 Dec 2024
BlackRock, Inc. 5.6% $8.37M 2.78M BlackRock, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.9% $5.7M 1.89M Millennium Management LLC 31 Dec 2024

Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 34.4M $182M +$11.6M $5.31 131
2025 Q2 32.8M $112M +$8.6M $3.43 121
2025 Q1 30.4M $90M +$2.95M $2.96 116
2024 Q4 29.4M $89.6M -$7.8M $3.05 111
2024 Q3 29.7M $75.9M -$5.78M $2.55 100
2024 Q2 31M $101M -$1.24M $3.26 98
2024 Q1 29.7M $158M +$17.1M $5.30 93
2023 Q4 26.6M $115M +$4.77M $4.33 82
2023 Q3 25.7M $67.6M -$2.43M $2.63 67
2023 Q2 26.6M $93.8M -$4.38M $3.53 67
2023 Q1 27.9M $86.1M -$528K $3.09 77
2022 Q4 27.5M $116M -$139K $4.23 86
2022 Q3 27.6M $65.5M -$1.99M $2.37 71
2022 Q2 27.9M $79.5M -$4.14M $2.85 77
2022 Q1 29.9M $86.1M -$477K $2.88 95
2021 Q4 30.3M $92.2M -$39.5M $3.04 96
2021 Q3 32.2M $225M -$28.7M $7.01 112
2021 Q2 34.8M $319M -$17.3M $9.18 118
2021 Q1 36.6M $356M +$13.7M $9.72 117
2020 Q4 35.3M $362M -$9.27M $10.26 120
2020 Q3 38.7M $390M +$12.9M $10.09 128
2020 Q2 35.1M $366M -$6.71M $10.43 124
2020 Q1 36.6M $309M +$43.6M $8.44 121
2019 Q4 31.3M $274M -$64.6M $8.75 129
2019 Q3 36.6M $394M +$16.1M $10.77 138
2019 Q2 34.8M $442M -$104M $12.71 132
2019 Q1 34.2M $1.32B +$17.6M $38.79 156
2018 Q4 35.2M $716M -$228M $20.35 137
2018 Q3 35.6M $1.63B -$26.4M $45.85 154
2018 Q2 35.9M $2.13B -$1.06M $59.15 169
2018 Q1 35.6M $2.42B -$81.2M $68.05 168
2017 Q4 36.2M $3.57B -$112M $98.85 194
2017 Q3 36.7M $4.39B +$170M $119.75 170
2017 Q2 35.5M $3.1B +$57.5M $87.40 152
2017 Q1 38M $1.41B +$191M $37.20 135
2016 Q4 34.9M $1.07B +$72.9M $30.70 128
2016 Q3 30M $2.01B +$5.54M $67.05 145
2016 Q2 31.8M $948M +$39.6M $29.79 107
2016 Q1 30.4M $893M -$135M $29.37 114
2015 Q4 32.3M $2.53B +$178M $78.40 131
2015 Q3 30.2M $2.27B -$40.7M $75.36 159
2015 Q2 30.4M $3.55B -$40.1M $116.75 193
2015 Q1 29.1M $6.87B +$478M $236.11 194
2014 Q4 27.1M $5.14B +$68.5M $189.27 183
2014 Q3 26.7M $6.37B +$472M $238.57 182
2014 Q2 25.4M $1.67B -$43.1M $66.00 132
2014 Q1 25.1M $2.61B +$107M $104.14 130